NASDAQ:TNGX Tango Therapeutics Q4 2024 Earnings Report $5.93 -0.18 (-2.95%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$5.92 -0.01 (-0.17%) As of 07/11/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Tango Therapeutics EPS ResultsActual EPS-$0.35Consensus EPS -$0.32Beat/MissMissed by -$0.03One Year Ago EPSN/ATango Therapeutics Revenue ResultsActual Revenue$4.12 millionExpected Revenue$7.84 millionBeat/MissMissed by -$3.72 millionYoY Revenue GrowthN/ATango Therapeutics Announcement DetailsQuarterQ4 2024Date2/27/2025TimeBefore Market OpensConference Call DateThursday, February 27, 2025Conference Call Time7:00AM ETUpcoming EarningsTango Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Tango Therapeutics Earnings HeadlinesTango Therapeutics doses first patient in cancer drug combo trialJune 29, 2025 | uk.investing.comTango Therapeutics Shares Climb After First Patient Dosed in Pancreatic, Lung Cancer TrialJune 27, 2025 | marketwatch.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. | Porter & Company (Ad)Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung CancerJune 27, 2025 | globenewswire.comTango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? - NasdaqJune 25, 2025 | nasdaq.comTango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trialsJune 16, 2025 | investing.comSee More Tango Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tango Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tango Therapeutics and other key companies, straight to your email. Email Address About Tango TherapeuticsTango Therapeutics (NASDAQ:TNGX) (NASDAQ: TNGX) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. Founded in 2017, Tango is focused on harnessing the power of synthetic lethality to discover and develop precision oncology therapies. By identifying tumor-specific genetic dependencies, the company aims to create targeted treatments that exploit vulnerabilities unique to cancer cells while sparing healthy tissues. The company’s proprietary discovery engine integrates CRISPR-based genome-wide screening with advanced computational biology to pinpoint novel synthetic lethal interactions. Tango’s pipeline includes multiple wholly owned programs targeting DNA damage repair pathways, as well as immuno-oncology and metabolic vulnerabilities. Lead assets are advancing through preclinical validation and into early-stage clinical trials, with several IND submissions anticipated in the coming years. Tango has forged strategic collaborations with leading pharmaceutical partners to co-develop select programs and expand its therapeutic reach. These alliances leverage Tango’s expertise in target identification alongside partners’ clinical development and commercialization capabilities. The company is led by CEO Debora Barton, Ph.D., whose leadership team brings deep experience in oncology drug discovery, translational research and global biopharmaceutical operations. Operating primarily in the United States, Tango maintains research and development facilities in Kendall Square and collaborates with academic institutions and contract research organizations worldwide. Committed to advancing next-generation cancer medicines, the company’s mission is to deliver differentiated therapies that offer new treatment options for patients with high unmet medical need across diverse tumor types.Written by Jeffrey Neal JohnsonView Tango Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
